Mohan’s research reveals that the beneficial effects of EGCG in mitigating DN are mediated mainly through its ability to activate the Nrf2/ARE pathway at multiple stages, i.e., by downregulating Keap1 and boosting the nuclear Nrf2 level by disrupting the Nrf2-Keap1 interaction [129]. Here, KEAP1 is linked to liver dysplastic nodule.